Overexpression of SOCS-2 and SOCS-3 genes reverses erythroid overgrowth and IGF-I hypersensitivity of primary polycythemia vera (PV) cells

References

• Adamson J W, Fialkow P J, Murphy S, Prchal J F, Steinmann L. Polycythemia vera: stem cell and probable clonal origin of the disease. New Engl J Med 1976; 295: 913–916
   PubMed Web of Science ®Google Scholar
• Golde D W, Cline M J. Pathogenesis of polycythemia vera – new concepts. Am J Hematol 1976; 1: 351–355
   PubMed Web of Science ®Google Scholar
• Spivak J L. Polycythemia vera: myths, mechanisms, and management. Blood 2002; 100: 4272–4290
   PubMed Web of Science ®Google Scholar
• Vaquez H. Sur une forme speciale de cyanose s'accompagnant d'hyperglobulie excessive et persistante. Comptes Rendus de la Societé dè Biologie (Paris) 1892; 44: 384–388
   Google Scholar
• Osler W. Chronic cyanosis, with polycythemia and enlarged spleen: a new clinical entity. Am J Med Sci 1903; 126: 176–201
   Google Scholar
• Berlin N I. Diagnosis and classification of the polycythemias. Semin Hematol 1974; 12: 339–351
   Web of Science ®Google Scholar
• Spivak J L, Pham J, Isaacs M, Hankins W D. Erythropoietin is both a mitogen and a survival factor. Blood 1991; 77: 1228–1233
   PubMed Web of Science ®Google Scholar
• de Klerk G, Rosengarten P C, Vet R J, Goudsmit R. Serum erythropoietin (ESF) titer in polycythemia. Blood 1981; 58: 1171–1174
   PubMed Web of Science ®Google Scholar
• Carneskog J, Kutti J, Wadenvik H, Lundberg P A, Lindstedt G. Plasma erythropoietin by high detectability immunoradiometric assay in untreated and treated patients with polycythemia vera and essential thrombocythemia. Eur J Haematol 1998; 60: 278–282
   PubMed Web of Science ®Google Scholar
• Prchal J F, Axelrad A A. Bone-marrow responses in polycythemia vera. New Engl J Med 1974; 290: 1382
   PubMed Web of Science ®Google Scholar
• Fisher M J, Prchal J F, Prchal J T, D'Andrea A D. Anti-erythropoietin (EPO) receptor monoclonal antibodies distinguish EPO-dependent and EPO-independent erythroid progenitors in polycythemia vera. Blood 1994; 84: 1982–1991
   PubMed Web of Science ®Google Scholar
• Correa P N, Eskinazi D, Axelrad A A. Circulating erythroid progenitors in Polycythemia vera are hypersensitive to IGF-I in vitro: studies in an improved serum-free medium. Blood 1994; 83: 99–112
   PubMed Web of Science ®Google Scholar
• Axelrad A A. Growth factor signaling in Polycythemia vera cells: specific hypersensitivities to cytokines in the chronic myeloproliferative disorders. Molecular Basis of Chronic Myeloproliferative Disorders, P E Petrides, H L Pahl. Springer-Verlag, Berlin 2004; 65–73
   Google Scholar
• Werther G A, Haynes K, Johnson G R. Insulin-like growth factors promote DNA synthesis and support cell viability in fetal hemopoietic tissue by paracrine mechanisms. Growth Factors 1990; 3: 171–179
   PubMedGoogle Scholar
• Le Roith D, Werner H, Beitner-Johnson D, Roberts C T, Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143–163
   PubMed Web of Science ®Google Scholar
• Muta K, Krantz S B. Apoptosis of human erythroid colony-forming cells is decreased by stem cell factor and insulin-like growth factor I as well as by erythropoietin. J Cell Physiol 1993; 156: 264–271
   PubMed Web of Science ®Google Scholar
• Peruzzi F, Prisca M, Dews M, Salomoni P, Grassilli E, Romano G, et al. Multiple signaling pathways of the insulin-like growth factor I receptor in protection from apoptosis. Mol Cell Biol 1999; 19: 7203–7215
   PubMed Web of Science ®Google Scholar
• Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochem Biophys Acta 1997; 1332: F105–F126
   PubMed Web of Science ®Google Scholar
• Valentinis B, Romano G, Peruzzi F, Morrione A, Prisco M, Soddu S, et al. Growth and differentiation signals by the insulin- like growth factor-I receptor in hemopoietic cells are mediated through different pathways. J Biol Chem 1999; 274: 12423–12430
   PubMed Web of Science ®Google Scholar
• Mirza A M, Correa P N, Axelrad A A. Increased basal and induced tyrosine phosphorylation of the insulin-like growth factor I receptor β subunit in circulating mononuclear cells of patients with Polycythemia vera. Blood 1995; 86: 877–882
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic J. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148
   PubMed Web of Science ®Google Scholar
• Baxter E J, Scott L M, Campbell P J, East C, Fourouclas N, Swanton S, et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061
   PubMed Web of Science ®Google Scholar
• Levine R L, Wadleigh M, Cools J, Ebert B, Wernig G, Huntly B, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser A S, Teo S, Tiedt R, Passweg J, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790
   PubMed Web of Science ®Google Scholar
• Axelrad A A, Eskinazi D, Correa P N, Amato D. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHuMGDF) in essential thrombocythemia. Blood 2000; 96: 3310–3321
   PubMed Web of Science ®Google Scholar
• Axelrad A A, Eskinazi D, Amato D. Does hypersensitivity of progenitor cells to normal cytokine(s) play a role in the pathogenesis of idiopathic myelofibrosis with myeloid metaplasia?. Blood 1999; 94: 2886
   Google Scholar
• Staerk J, Kallin A, Demoulin J B, Vainchenker W, Constantinescu S N. JAK1 and Tyk2 activation by the homologous Polycythemia vera JAK2 V617F mutation: cross talk with IGFI receptor. J Biol Chem 2005; 280: 41893–41899
   PubMed Web of Science ®Google Scholar
• Kralovics R, Stockton D W, Prchal J T. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003; 102: 3793–3796
   PubMed Web of Science ®Google Scholar
• Kovanen P E, Leonard W J. Inhibitors keep cytokines in check. Curr Biol 1999; 9: R899–R902
   PubMed Web of Science ®Google Scholar
• Krebs D L, Hilton D J. SOCS: physiological suppressors of cytokine signaling. J Cell Sci 2000; 113: 2813–2819
   PubMed Web of Science ®Google Scholar
• Hilton D J, Richardson R T, Alexander W S, Viney E M, Willson T A, Sprigg N S, et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA 1998; 95: 114–119
   PubMed Web of Science ®Google Scholar
• Zhang J G, Farley A, Nicholson S E, Willson T A, Zugaro L M, Simpson R J, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA 1999; 96: 2071–2076
   PubMed Web of Science ®Google Scholar
• Rui L, Yuan M, Frantz D, Shoelson S, White M F. SOCS1 and SOCS3 block signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002; 277: 42394–42398
   PubMed Web of Science ®Google Scholar
• Emanuelli B, Peraldi P, Filloux C, Sowka-Verhelle D, Hilton D, Van Obberghen E. SOCS-3 is an insulin-induced negative regulator of insulin signaling. J Biol Chem 2000; 275: 15985–15991
   PubMedGoogle Scholar
• Correa P N, Axelrad A A. Production of erythropoietic bursts by progenitor cells from adult human peripheral blood in an improved serum-free medium: role of IGF-I. Blood 1991; 78: 2823–2833
   PubMed Web of Science ®Google Scholar
• Zong C S, Chan J, Levy D E, Horvath C, Sadowski H B, Wang L H. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem 2000; 275: 15099–15105
   PubMed Web of Science ®Google Scholar
• Roder S, Steimle C, Meinhardt G, Pahl H L. STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp Hematol 2001; 29: 694–702
   PubMed Web of Science ®Google Scholar
• Dey B R, Spence S L, Nissley P, Furlanetto R W. Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J Biol Chem 1998; 273: 24095–24101
   PubMed Web of Science ®Google Scholar
• Magrangeas F, Boisteau O, Denis S, Jasques Y, Minvielle S. Negative cross-talk between interleukin-3 and interleukin-11 is mediated by suppressor of cytokine signalling-3 (SOCS-3). Biochem J 2001; 353: 223–230
   PubMed Web of Science ®Google Scholar
• Greenhalgh C J, Metcalf D, Thaus A L, Corbin J E, Uren R, Morgan P O, et al. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem 2002; 277: 40181–40184
   PubMed Web of Science ®Google Scholar
• Ram P A, Waxman K J. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem 1999; 274: 35553–35561
   PubMed Web of Science ®Google Scholar
• Adams T E, Hansen J A, Starr R, Nicola N A, Hilton D J, Billestrup N. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J Biol Chem 1998; 273: 1285–1287
   PubMedGoogle Scholar
• Favre H, Benhamou A, Finidori J, Kelly P A, Edery M. Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett 1999; 453: 63–66
   PubMed Web of Science ®Google Scholar
• Goldshmit Y, Walters C E, Scott H J, Greenhalgh G J, Turnley A M. SOCS 2 induces neurite outgrowth by regulation of EGF receptor activation. J Biol Chem 2004; 279: 16349–16355
   PubMed Web of Science ®Google Scholar